subject area of
- 28th Bethesda Conference. Task force 5: Assessment, approval, and regulation of new technology Academic Article
- Advances in thrombolytic therapy for acute myocardial-infarction Academic Article
- At-home genetic tests Academic Article
- Carbohydrate moieties as vaccine candidates: Targeting the sweet spot in the immune response Academic Article
- Clinical development success rates for investigational drugs Academic Article
- Discovery of novel drugs for promising targets Academic Article
- Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus Academic Article
- FDA-approved drugs and other compounds tested as inhibitors of human glutathione transferase P1-1 Academic Article
- Identification of new inhibitors for human hematopoietic prostaglandin D-2 synthase among FDA-approved drugs and other compounds Academic Article
- Market watch: Upcoming market catalysts in Q2 2014 Academic Article
- NCCN Oncology Risk Evaluation and Mitigation Strategies White Paper: recommendations for stakeholders Academic Article
- Observational versus randomized medical device testing before and after market approval - the atherectomy-versus-angioplasty controversy Academic Article
- Proteasome inhibitor drugs on the rise Academic Article
- Results of directional coronary atherectomy during multicenter preapproval testing Academic Article